EPIRUBICIN Side Effects

7003519-2 | Nail Disorder, Palmar-plantar Erythrodysaesthesia Syndrome, Rash Maculo-papular, Skin Hyperpigmentation
on Aug 31, 2010 Female patient from TURKEY , 63 years of age, was diagnosed with breast cancer stage iii and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: nail disorder, palmar-plantar erythrodysaesthesia syndrome, rash maculo-papular, skin hyperpigmentation. Epirubicin dosage: (145 Mg/m2, On Day 1, Repeated Every Three Weeks). During the same period patient was treated with FLUOROURACIL ((720 Mg/m2, On Day 1, Repeated Every Three Weeks)) (View Fluorouracil Review and Fluorouracil Label ), CYCLOPHOSPHAMIDE ((720 Mg/m2, On Day 1, Repeated Every Three Weeks)) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6982076-0 | Abdominal Distension, Bladder Disorder, Bladder Fibrosis, Bladder Necrosis, Bladder Perforation, Cellulitis, Chills, Cystitis Noninfective, Dysuria
Patient was taking Epirubicin (View Usage). Patient had the following side effects: abdominal distension, bladder disorder, bladder fibrosis, bladder necrosis, bladder perforation, cellulitis (What is cellulitis?), chills, cystitis noninfective, dysuria on Aug 24, 2010 from GREECE Additional patient health information: Male patient , 73 years of age, was diagnosed with bladder cancer (What is bladder cancer?) and. Epirubicin dosage: Intravesical. During the same period patient was treated with CEPHALOSPORIN (CEPHALOSPORINS AND RELATED SUBSTANCES) (CEPHALOSPORINS (View Cephalosporin (cephalosporins And Related Substances) (cephalosporins Review and Cephalosporin (cephalosporins And Related Substances) (cephalosporins Label ).

6982075-9 | Abdominal Distension, Bladder Perforation, Cellulitis, Malaise, Pyrexia
Adverse event was reported on Aug 24, 2010 by a Male patient taking Epirubicin (View Usage) (Dosage: Intravesical) was diagnosed with bladder cancer (What is bladder cancer?) and. Location: GREECE , 82 years of age, After Epirubicin was administered, patient had the following side effects: abdominal distension, bladder perforation, cellulitis (What is cellulitis?), malaise, pyrexia.

6963699-1 | Alopecia, Anaemia, Back Pain, Bacteraemia, Bacterial Infection, Cellulitis, Coagulopathy, Effusion, Hepatic Function Abnormal
on Aug 10, 2010 Female patient from BULGARIA , 56 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: alopecia, anaemia, back pain (What is back pain?), bacteraemia, bacterial infection (What is bacterial infection?), cellulitis (What is cellulitis?), coagulopathy, effusion, hepatic function abnormal. Epirubicin dosage: (80 Mg/m2). During the same period patient was treated with DOCETAXEL ((80 Mg/m2)) (View Docetaxel Review and Docetaxel Label ), GRANULOCYTE COLONY STIMUALTING FACTOR (GRANULOCYTE COLONY STIMUALTING (View Granulocyte Colony Stimualting Factor (granulocyte Colony Stimualting Review and Granulocyte Colony Stimualting Factor (granulocyte Colony Stimualting Label ). Patient was hospitalized.


6963669-3 | Alopecia, Anaemia, Bacteraemia, Coagulopathy, Dyspnoea, Hepatic Function Abnormal, Neutropenia, Pain, Pruritus
on Aug 10, 2010 Female patient from BULGARIA , 56 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient had the following side effects: alopecia, anaemia, bacteraemia, coagulopathy, dyspnoea, hepatic function abnormal, neutropenia, pain (What is pain?), pruritus. Epirubicin dosage: (80 Mg/m2). During the same period patient was treated with DOCETAXEL ((80 Mg/m2)) (View Docetaxel Review and Docetaxel Label ), GRANULOCYTE COLONY STIMULATING FACTOR (View Granulocyte Colony Stimulating Factor Review and Granulocyte Colony Stimulating Factor Label ). Patient was hospitalized.

6956041-3 | Abdominal Distension, Bladder Catheterisation, Bladder Perforation, Cellulitis, Chills, Dysuria, Extravasation, Fibrosis, Malaise
Patient was taking Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: abdominal distension, bladder catheterisation, bladder perforation, cellulitis (What is cellulitis?), chills, dysuria, extravasation, fibrosis, malaise on Aug 20, 2010 from GREECE Additional patient health information: Male patient , 73 years of age, was diagnosed with bladder transitional cell carcinoma and. Epirubicin dosage: 2 Instillations. Patient was hospitalized.

6875632-1 | Breast Cancer Metastatic, Cardiac Failure
Adverse event was reported on Jul 19, 2010 by a Female patient taking Epirubicin (View Usage) (Dosage: ) was diagnosed with breast cancer metastatic and. Location: UNITED KINGDOM , 42 years of age, weighting 163.1 lb, Patient experienced the following unwanted or unexpected effects: breast cancer metastatic, cardiac failure. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ).

6786934-1 | Breast Cancer Female, Circulatory Collapse, Diabetes Mellitus, Hypoglycaemia, Lymphadenopathy, Lymphocyte Count Decreased, Pneumonia, Treatment Noncompliance, White Blood Cell Count Decreased
on Jun 10, 2010 Female patient from UNITED KINGDOM , 52 years of age, was diagnosed with breast cancer (What is breast cancer?), schizophrenia and was treated with Epirubicin (View Usage). Patient had the following side effects: breast cancer female, circulatory collapse, diabetes mellitus, hypoglycaemia, lymphadenopathy, lymphocyte count decreased, pneumonia (What is pneumonia?), treatment noncompliance, white blood cell count decreased. Epirubicin dosage: 4 Cycles,. During the same period patient was treated with CYCLOPHOSPHAMIDE (4 Cycles,) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (4 Cycles,) (View Docetaxel Review and Docetaxel Label ), CLOZARIL (Oral, 400 Mg Oral) (View Clozaril Review and Clozaril Label ), (AMITRIPTYLINE) (View (amitriptyline) Review and (amitriptyline) Label ), ASACOL (View Asacol Review and Asacol Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ).

6768089-2 | Breast Cancer, Circulatory Collapse, Diabetes Mellitus, Hypoglycaemia, Lymphocyte Count Decreased, Mastectomy, Pneumonia, Treatment Noncompliance, White Blood Cell Count Decreased
on Jun 09, 2010 Female patient from UNITED KINGDOM , 52 years of age, was diagnosed with schizophrenia and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: breast cancer (What is breast cancer?), circulatory collapse, diabetes mellitus, hypoglycaemia, lymphocyte count decreased, mastectomy (What is mastectomy?), pneumonia (What is pneumonia?), treatment noncompliance, white blood cell count decreased. Epirubicin dosage: . During the same period patient was treated with CLOZAPINE (View Clozapine Review and Clozapine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

6765763-9 | Breast Cancer Metastatic, Cardiac Failure
Patient was taking Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: breast cancer metastatic, cardiac failure on Jun 02, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 42 years of age, weighting 163.1 lb, was diagnosed with breast cancer metastatic and. Epirubicin dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6736291-1 | Adenocarcinoma, Dysphagia, Dysphonia, Malignant Pleural Effusion, Metastatic Neoplasm, Pneumonia, White Blood Cell Count Decreased
Adverse event was reported on May 20, 2010 by a Male patient taking Epirubicin (View Usage) (Dosage: ) . Location: UNITED STATES , weighting 152.1 lb, Patient had the following side effects: adenocarcinoma, dysphagia, dysphonia, malignant pleural effusion, metastatic neoplasm, pneumonia (What is pneumonia?), white blood cell count decreased. During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), ALTACE (View Altace Review and Altace Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ). Patient was hospitalized.

6725433-X | Neutropenia
on May 13, 2010 Female patient from UNITED STATES , weighting 193.6 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: neutropenia. Epirubicin dosage: 205 Mg Iv Q X 4 3 Weeks. During the same period patient was treated with CYCLOPHOSPHAMIDE (1025 Mg Iv X4 3 Weeks) (View Cyclophosphamide Review and Cyclophosphamide Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ).

6725423-7 | Febrile Neutropenia, Pyrexia
on May 13, 2010 Female patient from UNITED STATES , weighting 190.7 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, pyrexia. Epirubicin dosage: 205 Mg Iv Q 3 Wks. During the same period patient was treated with CYCLOPHOSPHAMIDE (1025 Mg Iv Q 3 Wks) (View Cyclophosphamide Review and Cyclophosphamide Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ).

6724498-9 | Neutropenia
Patient was taking Epirubicin (View Usage). Patient had the following side effects: neutropenia on May 06, 2010 from GREECE Additional patient health information: Female patient , 55 years of age, weighting 154.3 lb, was diagnosed with breast cancer (What is breast cancer?) and. Epirubicin dosage: . During the same period patient was treated with ONDANSETRON (View Ondansetron Review and Ondansetron Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ).

6707562-X | Neutropenia
Adverse event was reported on Apr 29, 2010 by a Female patient taking Epirubicin (View Usage) (Dosage: ) was diagnosed with breast cancer (What is breast cancer?) and. Location: GREECE , 55 years of age, weighting 154.3 lb, After Epirubicin was administered, patient had the following side effects: neutropenia. During the same period patient was treated with ONDANSETRON (View Ondansetron Review and Ondansetron Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ).

6693016-6 | Neutropenia
on Apr 08, 2010 Female patient from GREECE , 65 years of age, weighting 154.3 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenia. Epirubicin dosage: . During the same period patient was treated with ONDANSETRON (View Ondansetron Review and Ondansetron Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), FLUOROURACILE (View Fluorouracile Review and Fluorouracile Label ).

6599801-3 | Alopecia, Atrioventricular Block Complete, Atrioventricular Block Second Degree, Bradycardia, Cardiotoxicity, Mastectomy, Ventricular Extrasystoles
on Jan 29, 2010 Female patient from UNITED KINGDOM , 47 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient had the following side effects: alopecia, atrioventricular block complete, atrioventricular block second degree, bradycardia, cardiotoxicity, mastectomy (What is mastectomy?), ventricular extrasystoles. Epirubicin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), TAXOL (View Taxol Review and Taxol Label ), DESFLURANE (DESFLURANE) (DESFLURANE) (View Desflurane (desflurane) (desflurane) Review and Desflurane (desflurane) (desflurane) Label ), REMIFENTANIL (REMIFENTANIL) (REMIFENTANIL) (View Remifentanil (remifentanil) (remifentanil) Review and Remifentanil (remifentanil) (remifentanil) Label ). Patient was hospitalized.

6598057-5 | Breast Cancer Female, Circulatory Collapse, Diabetes Mellitus, Fall, Hypoglycaemia, Lymphocyte Count Decreased, Malaise, Pneumonia
Patient was taking Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: breast cancer female, circulatory collapse, diabetes mellitus, fall (What is fall?), hypoglycaemia, lymphocyte count decreased, malaise, pneumonia (What is pneumonia?) on Feb 09, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 52 years of age, was diagnosed with breast cancer (What is breast cancer?), schizophrenia and. Epirubicin dosage: 4 Cycles,. During the same period patient was treated with CYCLOPHOSPHAMIDE (4 Cycles,) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (4 Cycles,) (View Docetaxel Review and Docetaxel Label ), CLOZARIL (Oral; 400 Mg) (View Clozaril Review and Clozaril Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ), ASACOL (View Asacol Review and Asacol Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ).

6587732-4 | B Precursor Type Acute Leukaemia, Stem Cell Transplant
Adverse event was reported on Jan 25, 2010 by a Female patient taking Epirubicin (View Usage) (Dosage: Four Cycles) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED STATES , 56 years of age, Patient experienced the following unwanted or unexpected effects: b precursor type acute leukaemia, stem cell transplant. During the same period patient was treated with CYCLOPHOSPHAMIDE (Four Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (Three Cycles) (View Docetaxel Review and Docetaxel Label ), THERAPEUTIC RADIOPHARMACEUTICALS (View Therapeutic Radiopharmaceuticals Review and Therapeutic Radiopharmaceuticals Label ). Patient was hospitalized.

6578784-6 | Coma, Progressive Multifocal Leukoencephalopathy
on Jan 18, 2010 Female patient from UNITED KINGDOM , 65 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient had the following side effects: coma, progressive multifocal leukoencephalopathy. Epirubicin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), LETROZOLE (View Letrozole Review and Letrozole Label ), TAXOTERE (View Taxotere Review and Taxotere Label ). Patient was hospitalized.

6553017-5 | Alopecia, Atrioventricular Block Complete, Atrioventricular Block Second Degree, Procedural Complication, Ventricular Extrasystoles
on Jan 04, 2010 Female patient from UNITED KINGDOM , 47 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: alopecia, atrioventricular block complete, atrioventricular block second degree, procedural complication, ventricular extrasystoles. Epirubicin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), TAXOL (View Taxol Review and Taxol Label ). Patient was hospitalized.

6551220-1 | Abdominal Pain, Blood Pressure Decreased, Febrile Neutropenia, Haemoglobin Decreased, Tachycardia
Patient was taking Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), blood pressure decreased, febrile neutropenia, haemoglobin decreased, tachycardia on Jan 05, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 29 years of age, . Epirubicin dosage: 165 Mg, 1 Day, Intravenous. During the same period patient was treated with FLUOROURACIL (820 Mg, 1 Day, Intravenous) (View Fluorouracil Review and Fluorouracil Label ), CYCLOPHOSPHAMIDE (820 Mg, 1 Day, Intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

6551154-2 | Tumour Flare
Adverse event was reported on Jan 12, 2010 by a Female patient taking Epirubicin (View Usage) (Dosage: (six Courses)) was diagnosed with breast cancer (What is breast cancer?) and. Location: TAIWAN, PROVINCE OF CHINA , 47 years of age, Patient had the following side effects: tumour flare. During the same period patient was treated with TAXOTERE (DOCETAXEL) (DOCETAXEL) (View Taxotere (docetaxel) (docetaxel) Review and Taxotere (docetaxel) (docetaxel) Label ), ENDOXAN (CYCLOPHOSPHAMIDE) (CYCLOPHOSPHAMIDE) (View Endoxan (cyclophosphamide) (cyclophosphamide) Review and Endoxan (cyclophosphamide) (cyclophosphamide) Label ).

6423663-8 | Breast Cancer Female, Circulatory Collapse, Diabetes Mellitus, Hypoglycaemia, Lymphocyte Count Decreased, Pneumonia, Treatment Noncompliance, White Blood Cell Count Decreased
on Oct 19, 2009 Female patient from UNITED KINGDOM , 52 years of age, was diagnosed with breast cancer (What is breast cancer?), schizophrenia and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: breast cancer female, circulatory collapse, diabetes mellitus, hypoglycaemia, lymphocyte count decreased, pneumonia (What is pneumonia?), treatment noncompliance, white blood cell count decreased. Epirubicin dosage: 4 Cycles. During the same period patient was treated with CLOZARIL (Oral) (View Clozaril Review and Clozaril Label ), CYCLOPHOSPHAMIDE (4 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (4 Cycles) (View Docetaxel Review and Docetaxel Label ), (AMITRIPTYLINE) (View (amitriptyline) Review and (amitriptyline) Label ), ASACOL (View Asacol Review and Asacol Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), ESCITALOPRAM (View Escitalopram Review and Escitalopram Label ).

6416080-8 | Abscess, Bone Infarction, Cellulitis, Diabetes Mellitus, Febrile Neutropenia, Osteomyelitis, Osteonecrosis, Skin Graft, Staphylococcal Infection
on Oct 17, 2009 Female patient from TAIWAN, PROVINCE OF CHINA , 37 years of age, was diagnosed with breast cancer female and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: abscess (What is abscess?), bone infarction, cellulitis (What is cellulitis?), diabetes mellitus, febrile neutropenia, osteomyelitis, osteonecrosis (What is osteonecrosis?), skin graft, staphylococcal infection (What is staphylococcal infection?). Epirubicin dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), ENDOXAN /00021101/ (View Endoxan /00021101/ Review and Endoxan /00021101/ Label ), ZOLADEX (View Zoladex Review and Zoladex Label ), TAMOXIFEN (View Tamoxifen Review and Tamoxifen Label ), ORAL ANTIDIABETICS (View Oral Antidiabetics Review and Oral Antidiabetics Label ). Patient was hospitalized.

6408478-9 | Breast Cancer, Circulatory Collapse, Diabetes Mellitus, Hypoglycaemia, Lymphocyte Count Decreased, Mastectomy, Pneumonia, Treatment Noncompliance, White Blood Cell Count Decreased
Patient was taking Epirubicin (View Usage). Patient had the following side effects: breast cancer (What is breast cancer?), circulatory collapse, diabetes mellitus, hypoglycaemia, lymphocyte count decreased, mastectomy (What is mastectomy?), pneumonia (What is pneumonia?), treatment noncompliance, white blood cell count decreased on Oct 15, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 52 years of age, was diagnosed with schizophrenia and. Epirubicin dosage: . During the same period patient was treated with CLOZAPINE (View Clozapine Review and Clozapine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

6343900-8 | Dysgeusia, Tongue Discolouration, Tongue Oedema
Adverse event was reported on Aug 26, 2009 by a Female patient taking Epirubicin (View Usage) (Dosage: 152 Mg, Cyclic, Every 3 Weeks) was diagnosed with breast cancer (What is breast cancer?) and. Location: JAPAN , 42 years of age, After Epirubicin was administered, patient had the following side effects: dysgeusia, tongue discolouration, tongue oedema. During the same period patient was treated with FLUOROURACIL (760 Mg, Cyclic Every 3 Weeks) (View Fluorouracil Review and Fluorouracil Label ), ENDOXAN (760 Mg, Unk) (View Endoxan Review and Endoxan Label ), IMIDAPRIL HYDROCHLORIDE (Unk) (View Imidapril Hydrochloride Review and Imidapril Hydrochloride Label ), DECADRON (Unk) (View Decadron Review and Decadron Label ), DECADRON #1 (Unk) (View Decadron #1 Review and Decadron #1 Label ), RAMOSETRON HYDROCHLORIDE (Unk) (View Ramosetron Hydrochloride Review and Ramosetron Hydrochloride Label ).

6287452-X | Bone Marrow Necrosis, Myelodysplastic Syndrome
on Jul 20, 2009 Female patient from ITALY , 37 years of age, was diagnosed with liposarcoma and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow necrosis, myelodysplastic syndrome. Epirubicin dosage: . During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), THERAPEUTIC RADIOPHARMACEUTICALS (View Therapeutic Radiopharmaceuticals Review and Therapeutic Radiopharmaceuticals Label ). Patient was hospitalized.

6278388-9 | Body Temperature Increased, Neutrophil Count Decreased, White Blood Cell Count Decreased
on Jul 20, 2009 Female patient from UNITED STATES , 61 years of age, weighting 172.0 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). Patient had the following side effects: body temperature increased, neutrophil count decreased, white blood cell count decreased. Epirubicin dosage: 90mg/m2 Q3wk Iv Bolus. During the same period patient was treated with CYCLOPHOSPHAMIDE (600mg/m2 Q3wk Iv Bolus) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6220223-9 | Abdominal Pain Upper, Cardiac Failure, Chest Discomfort
Patient was taking Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: abdominal pain upper, cardiac failure, chest discomfort on May 21, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 49 years of age, weighting 166.7 lb, was diagnosed with breast cancer (What is breast cancer?) and. Epirubicin dosage: . During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VENLAFAXINE HYDROCHLORIDE (View Venlafaxine Hydrochloride Review and Venlafaxine Hydrochloride Label ). Patient was hospitalized.

6215474-3 | Hallucination, Visual
Adverse event was reported on May 15, 2009 by a Male patient taking Epirubicin (View Usage) (Dosage: 4.7619 Mg, 1 In 3 Weeks; Intravenous) was diagnosed with gastric cancer, mental disorder and. Location: UNITED KINGDOM , 59 years of age, weighting 189.2 lb, Patient experienced the following unwanted or unexpected effects: hallucination, visual. During the same period patient was treated with CARBAMAZEPINE (600 Mg, 2 In 1 Days, Oral) (View Carbamazepine Review and Carbamazepine Label ), CISPLATIN (5.7143 Mg, 1 In 3 Weeks; Intravenous) (View Cisplatin Review and Cisplatin Label ), OLANZAPINE (10 Mg, 1 In 1 Days, Oral) (View Olanzapine Review and Olanzapine Label ), PERPHENAZINE (8 Mg, 2 In 1 Days, Oral) (View Perphenazine Review and Perphenazine Label ), XELODA (2600 Mg, 2 In 1 Days, Oral) (View Xeloda Review and Xeloda Label ).

6213719-7 | Gastric Cancer, Hallucination, Visual
on May 15, 2009 Male patient from UNITED KINGDOM , 59 years of age, was diagnosed with gastric cancer, mental disorder and was treated with Epirubicin (View Usage). Patient had the following side effects: gastric cancer, hallucination, visual. Epirubicin dosage: 100 Mg, Intravenous. During the same period patient was treated with CISPLATIN (120 Mg, 3, Intravenous) (View Cisplatin Review and Cisplatin Label ), CAPECITABINE (1300 Mg, 2, Oral) (View Capecitabine Review and Capecitabine Label ), CARBAMAZEPINE (300 Mg, 2, Oral) (View Carbamazepine Review and Carbamazepine Label ), OLANZAPINE (10 Mg, 1, Oral) (View Olanzapine Review and Olanzapine Label ), PERPHENAZINE (4 Mg, 2, Oral) (View Perphenazine Review and Perphenazine Label ).

6203227-1 | Acute Lymphocytic Leukaemia, Haematocrit Decreased, Haemoglobin Decreased, Metastases To Liver, Platelet Count Decreased, Refusal Of Treatment By Patient
on May 12, 2009 Female patient from SOUTH AFRICA , 60 years of age, was diagnosed with metastases to bone, breast cancer (What is breast cancer?) and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: acute lymphocytic leukaemia, haematocrit decreased, haemoglobin decreased, metastases to liver, platelet count decreased, refusal of treatment by patient. Epirubicin dosage: (per Cycle). During the same period patient was treated with METHOTREXATE ((per Cycle, 6 Cycles)) (View Methotrexate Review and Methotrexate Label ), (PACLITAXEL) ((per Cycle )) (View (paclitaxel) Review and (paclitaxel) Label ), FLUOROURACIL ((per Cycle, 6 Cycles )) (View Fluorouracil Review and Fluorouracil Label ), CYCLOPHOSPHAMIDE ((per Cycle, 6 Cycles )) (View Cyclophosphamide Review and Cyclophosphamide Label ), (THERAPEUTIC RADIOPHARMACEUTICALS) (View (therapeutic Radiopharmaceuticals) Review and (therapeutic Radiopharmaceuticals) Label ).

6185190-5 | Chest Pain
Patient was taking Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?) on Apr 14, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 66 years of age, was diagnosed with gastric cancer and. Epirubicin dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), XELODA (View Xeloda Review and Xeloda Label ).

6170905-2 | Chest Pain
Adverse event was reported on Apr 14, 2009 by a Female patient taking Epirubicin (View Usage) (Dosage: ) was diagnosed with gastric cancer and. Location: UNITED KINGDOM , 66 years of age, Patient had the following side effects: chest pain (What is chest pain?). During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), CAPECITABINE (View Capecitabine Review and Capecitabine Label ).

6134248-5 | Thyroid Cancer
on Mar 10, 2009 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with rhabdomyosarcoma and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: thyroid cancer (What is thyroid cancer?). Epirubicin dosage: . During the same period patient was treated with DACTINOMYCIN (Intravenous) (View Dactinomycin Review and Dactinomycin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6120093-3 | Thyroid Cancer
on Feb 11, 2009 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with rhabdomyosarcoma and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: thyroid cancer (What is thyroid cancer?). Epirubicin dosage: . During the same period patient was treated with DACTINOMYCIN (Intravenous) (View Dactinomycin Review and Dactinomycin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6089723-9 | Hypotension, Toxic Epidermal Necrolysis, Urinary Tract Infection
Patient was taking Epirubicin (View Usage). Patient had the following side effects: hypotension, toxic epidermal necrolysis, urinary tract infection (What is urinary tract infection?) on Feb 11, 2009 from FRANCE Additional patient health information: Female patient , 46 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Epirubicin dosage: 90 Mg/m**2 Q3w Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (600 Mg/m**2 Cyc Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), AUGMENTIN (View Augmentin Review and Augmentin Label ), OFLOCKET (View Oflocket Review and Oflocket Label ). Patient was hospitalized.

6065683-1 | Metastases To Lymph Nodes, Radiation Exposure, Thyroid Cancer
Adverse event was reported on Jan 15, 2009 by a Male patient taking Epirubicin (View Usage) (Dosage: ) was diagnosed with rhabdomyosarcoma and. Location: UNITED KINGDOM , child 7 years of age, After Epirubicin was administered, patient had the following side effects: metastases to lymph nodes, radiation exposure, thyroid cancer (What is thyroid cancer?). During the same period patient was treated with DACTINOMYCIN (Intravenous) (View Dactinomycin Review and Dactinomycin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6055743-3 | Interstitial Lung Disease, Mucosal Inflammation, Neutropenia
on Jan 12, 2009 Male patient from ITALY , 68 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease, mucosal inflammation, neutropenia. Epirubicin dosage: . During the same period patient was treated with ETOPOSIDE (50mg/m2 Iv Day 1 On Weeks, 3,7, And 11) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6054970-9 | Thyroid Cancer
on Dec 31, 2008 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with rhabdomyosarcoma and was treated with Epirubicin (View Usage). Patient had the following side effects: thyroid cancer (What is thyroid cancer?). Epirubicin dosage: . During the same period patient was treated with DACTINOMYCIN (Intravenous) (View Dactinomycin Review and Dactinomycin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6049499-8 | Lymphadenopathy, Thyroid Cancer
Patient was taking Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: lymphadenopathy, thyroid cancer (What is thyroid cancer?) on Jan 05, 2009 from UNITED KINGDOM Additional patient health information: Male patient , child 7 years of age, was diagnosed with rhabdomyosarcoma and. Epirubicin dosage: 840 Mg;. During the same period patient was treated with ETOPOSIDE (1175 Mg;) (View Etoposide Review and Etoposide Label ), DACTINOMYCIN (2.52 Mg;) (View Dactinomycin Review and Dactinomycin Label ), CARBOPLATIN (840 Mg;) (View Carboplatin Review and Carboplatin Label ), IFOSFAMIDE (18480 Mg;) (View Ifosfamide Review and Ifosfamide Label ), VINCRISTINE (10.92 Mg;) (View Vincristine Review and Vincristine Label ).

6037812-7 | Infection, Mucosal Inflammation, Osteonecrosis
Adverse event was reported on Dec 17, 2008 by a Female patient taking Epirubicin (View Usage) (Dosage: ) . Location: CANADA , 70 years of age, Patient experienced the following unwanted or unexpected effects: infection (What is infection?), mucosal inflammation, osteonecrosis (What is osteonecrosis?). During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PAMIDRONATE DISODIUM (90 Mg, Intravenous) (View Pamidronate Disodium Review and Pamidronate Disodium Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), CAPECITABINE (View Capecitabine Review and Capecitabine Label ).

6037806-1 | Thyroid Cancer
on Jan 02, 2009 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with rhabdomyosarcoma, diagnostic procedure and was treated with Epirubicin (View Usage). Patient had the following side effects: thyroid cancer (What is thyroid cancer?). Epirubicin dosage: 840 Mg, 9 Cycles,. During the same period patient was treated with ETOPOSIDE (1176 Mg, 9 Cycles;) (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (18480 Mg, 9 Cycles;) (View Ifosfamide Review and Ifosfamide Label ), DACTINOMYCIN (2.52 Mg, 9 Cycles, Intravenous) (View Dactinomycin Review and Dactinomycin Label ), THERAPEUTIC RADIOPHARMACEUTICALS (View Therapeutic Radiopharmaceuticals Review and Therapeutic Radiopharmaceuticals Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ).

6037796-1 | Malignant Neoplasm Progression, Metastases To Bone, Metastases To Liver, Mucosal Inflammation, Osteonecrosis
on Dec 17, 2008 Female patient from UNITED KINGDOM , 70 years of age, was diagnosed with breast cancer metastatic and was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: malignant neoplasm progression, metastases to bone, metastases to liver, mucosal inflammation, osteonecrosis (What is osteonecrosis?). Epirubicin dosage: . During the same period patient was treated with FLUOROURACIL (Intravenous) (View Fluorouracil Review and Fluorouracil Label ), GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), METHOTREXATE (Intravenous) (View Methotrexate Review and Methotrexate Label ), PAMIDRONATE DISODIUM (90 Mg, Once A Month, Intravenous) (View Pamidronate Disodium Review and Pamidronate Disodium Label ), CAPECITABINE (View Capecitabine Review and Capecitabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

5961127-6 | Interstitial Lung Disease, Mucosal Inflammation, Neutropenia
Patient was taking Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease, mucosal inflammation, neutropenia on Nov 07, 2008 from ITALY Additional patient health information: Male patient , 68 years of age, was diagnosed with diffuse large b-cell lymphoma and. Epirubicin dosage: . During the same period patient was treated with ETOPOSIDE (See Image) (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), PREDNISONE (40 Mg/m^2, Every Other Day On Weeks 1-10 And Tapered During Weeks 11 And 12, Oral) (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (350 Mg/m^2 On Week 1, 5 And 9) (View Cyclophosphamide Review and Cyclophosphamide Label ), IMMUNOSUPPRESSANTS (NO INGREDIENTS/SUBSTANCES) (View Immunosuppressants (no Ingredients/substances) Review and Immunosuppressants (no Ingredients/substances) Label ), CO TRIMOXAZOLE (CO TRIMOXAZOLE) (View Co-trimoxazole (co-trimoxazole) Review and Co-trimoxazole (co-trimoxazole) Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

5960890-8 | Anaemia
Adverse event was reported on Nov 07, 2008 by a Male patient taking Epirubicin (View Usage) (Dosage: ) was diagnosed with diffuse large b-cell lymphoma, epstein-barr virus associated lymphoproliferative disorder and. Location: ITALY , 51 years of age, Patient had the following side effects: anaemia. During the same period patient was treated with ETOPOSIDE (50 Mg/m2, Day 1, Weeks 3,7,11, Intravenous, 100 Mg/m2, Days 2, 3, Weeks 3, 7, 11, Oral) (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (40 Mg/m2, Every Other Day, Weeks 1 Through 10, Tapered During Weeks 10 And 12, Oral) (View Prednisone Review and Prednisone Label ).

5959538-8 | Neutropenic Sepsis
on Oct 20, 2008 Female patient from UNITED KINGDOM , 70 years of age, was treated with Epirubicin (View Usage). After Epirubicin was administered, patient had the following side effects: neutropenic sepsis. Epirubicin dosage: Intravenous. During the same period patient was treated with CAPECITABINE (CAPECITABINE) (Intravenous) (View Capecitabine (capecitabine) Review and Capecitabine (capecitabine) Label ), CISPLATIN (Intravenous) (View Cisplatin Review and Cisplatin Label ).

5955177-3 | Neutropenic Sepsis
on Oct 20, 2008 Female patient from UNITED KINGDOM , 70 years of age, was treated with Epirubicin (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenic sepsis. Epirubicin dosage: Intravenous. During the same period patient was treated with CAPECITABINE (CAPECITABINE) (Intravenous) (View Capecitabine (capecitabine) Review and Capecitabine (capecitabine) Label ), CISPLATIN (Intravenous) (View Cisplatin Review and Cisplatin Label ).

5944535-9 | Dyspnoea, Hypersensitivity, Hypoaesthesia Oral, Micturition Urgency, Nasal Congestion, Urticaria
Patient was taking Epirubicin (View Usage). Patient had the following side effects: dyspnoea, hypersensitivity, hypoaesthesia oral, micturition urgency, nasal congestion, urticaria on Oct 29, 2008 from CANADA Additional patient health information: Female patient , 51 years of age, weighting 140.4 lb, was diagnosed with breast cancer (What is breast cancer?) and. Epirubicin dosage: 171 Mg Iv. During the same period patient was treated with FLUOROURACIL (850 Mg Iv) (View Fluorouracil Review and Fluorouracil Label ), ZOFRAN (View Zofran Review and Zofran Label ), DECADRON /00016001/. MFR: NOT SPECIFIED (View Decadron /00016001/. Mfr: Not Specified Review and Decadron /00016001/. Mfr: Not Specified Label ).